Novo Nordisk A/S New data will highlight the breadth of semaglutide evidence across the cardiometabolic spectrum, including obesity, type 2 diabetes, cardiovascular, kidney and fatty liver disease, and new data on Wegovy® pill, Wegovy® 7.2 mg and Ozempic® 2.0 mg Real-world evidence from the OCTANE study will provide insights into Wegovy® pill use in adults with overweight or obesity, including weight outcomes, treatment switching and patient-reported outcomes CagriSema and amylin-based pipeline data will provide new insights into appetite regulation, eating behaviour, food noise, body composition and bone health (bone remodelling mechanisms).
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.